The company operates two R\&D facilities in India and Thailand. The Surat center is DSIR-recognized and ISO certified, while the Thailand facility holds Thai GMP and CE certifications
The company markets its products in 76 countries, with the top 10 contributing 79.38% of revenue as of March 31, 2025. It follows direct, hybrid, and distributor-led models tailored to each region for effective global expansion
The company operates three integrated manufacturing facilities in India and Thailand, supported by over 1,500 employees. Lower labor costs in these regions provide a cost advantage, helping maintain competitive pricing and high-quality production
The company’s manufacturing facilities face risks like quality issues, outdated machinery, and infrastructure disruptions, which may raise costs or impact operations and reputation
The company must secure and maintain necessary permits and licenses for its manufacturing units. Delays or failures in doing so, or adverse inspection outcomes, could negatively impact its operations and financials
The company’s financials are reported in Indian Rupees, but revenues and expenses are influenced by foreign currencies due to international sales, imports, and operations of overseas subsidiaries
Also called a profit and loss statement, an income statement shows a company’s income, expenses, and how much profit or loss it has made over a specific accounting period. It provides a clear view of how well the business is running.
| Particulars (in Cr) | Jun 2026 | Q/Q Change |
|---|---|---|
| Operating Revenue | 351.67 | - |
| Other Income | 2.66 | - |
| Total Income | 354.33 | - |
| Total Expenditure | 303.09 | - |
| EBIDT | 51.24 | - |
| Depreciation | 20.41 | - |
| Interest | 6.55 | - |
| Tax | 9.19 | - |
| Net Profit | 14.57 | - |
A balance sheet is a financial statement that details a company’s assets, liabilities, and shareholders’ equity at a given time. It helps assess how financially strong and stable the company is.
| Particulars (in Cr) | Mar 2026 |
|---|---|
| Total Current Assets | 808.78 |
| Total Non-Current Assets | 467.65 |
| Fixed assets | 302.91 |
| Total Assets | 1,276.43 |
| Total Current liabilities | 488.79 |
| Total Non Current Liabilities | 85.35 |
| Total Equity Plus Liabilities | 1,276.43 |
| Total Shareholder Funds | 695.46 |
| Total Debt to Equity | 39.00% |
Cash flow highlights the cash or cash equivalents moving in and out of a company during a particular period. It provides a clear picture of how well a company manages its cash by tracking its operating, investing and financing activities.
| Particulars (in Cr) | Mar 2026 |
|---|---|
| Cash from Operating Activity | 105.19 |
| Cash from Financing Activities | -12.04 |
| Cash from Investing Activities | -130.03 |
| Net Cash Flow | -36.88 |
Sahajanand Medical Technologies was incorporated on September 30, 2001. The company is an R&D-driven; developer of Class III and Class C/D medical devices, focused on Vascular Intervention and Structural Heart solutions. Its portfolio includes coronary stents, balloons, TAVI, occluders, renal stents, and other specialized products
